Momenta Pharma (MNTA) Stock News
NASDAQ:MNTA - Nasdaq -
MNTA Latest News, Press Relases and Analysis
Are These The Top Pharmaceutical Stocks To Buy In October 2020?
Looking for long-term buys for your portfolio? Take a look at these 3 top pharmaceutical stocks.
The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Acceleron Pharma Inc (...
The Exact Trigger that Indicates Volatility in Momenta Pharmaceuticals Inc
The Trigger That Turned Momenta Pharmaceuticals Inc (NASDAQ:MNTA) Volatility into a Winner.
The Daily Biotech Pulse: Eton Snags Second FDA Nod For Month, Vaccine Updates from Moderna, CureVac
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc (...
Chesapeake Utilities +1.4% on move into SmallCap 600 (NYSE:CPK)
Chesapeake Utilities (NYSE:CPK) is up 1.4% after hours following news that it's moving into the S&P SmallCap 600.
Mentions: CPK
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
Sector ETF report for PSCH
MERGER INVESTIGATION ALERT: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – MNTA, VRTU, AIMT, MXIM
NEW YORK, NY / ACCESSWIRE / September 20, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Johnson & Johnson for $52.50 per share in cash. Visit our website to learn more about your rights and participate in an action:
Why Is Momenta (MNTA) Up 86.9% Since Last Earnings Report?
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – MNTA, BMCH, RST, AIMT
NEW YORK, NY / ACCESSWIRE / September 5, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Johnson & Johnson for $52.50 per share in cash. To learn more about your legal rights and options, visit:
Covid-19 Has Priced These Stocks at a Deep Discount
As Covid shut down large swaths of the non-digital economy, investors dumped stocks whose sales suffered most directly. But now the market seems willing to look ahead to these businesses’ revivals.
Immunovant, Following Rival's Acquisition News, Prices Stock Offering
Hot biotech stock Immunovant on Wednesday priced its secondary offering of 5.27 million shares at $33 per share, as IMVT stock trades near record highs.
INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – VAR, JCAP, MNTA, BYFC
NEW YORK, NY / ACCESSWIRE / September 1, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Varian Medical Systems, Inc. (NYSE:VAR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Siemens Healthineers AG for $177.50 per share. To learn more about your legal rights and options, visit:
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
Sector ETF report for PSCH
SHAREHOLDER ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – PRNB, MNTA, PTI, BLDR
NEW YORK, NY / ACCESSWIRE / August 29, 2020 /Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Principia Biopharma Inc. (NASDAQ:PRNB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sanofi for $100 per share. To learn more about your legal rights and options, visit:
Immunovant Up on Positive Data From Myasthenia Gravis Study
Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.
Buyout Excitement Is Already Priced Into Momenta Pharmaceuticals
Momenta Pharmaceuticals stock was thrust into the financial headlines and might look tempting, but don't forget that price is king.
Mentions: JNJ
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – CBMG, PRNB, MNTA, PTI
NEW YORK, NY / ACCESSWIRE / August 25, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Under the terms of the merger, Cellular Biomedicine
Housing Numbers Rise, and Lowe’s and Home Depot Stock Follow
Low interest rates and suburban refuges from Covid-19 are driving housing starts. Some indirect beneficiaries: the home-improvement chains. But how long will the boom last?
Are These The Top Pharmaceutical Stocks To Buy In August 2020?
Some of the most promising opportunities are found among pharmaceutical stocks.
ETFs in Focus on Momenta Buyout Deal With JNJ
A number of ETFs could be the best ways for investors to tap the opportunity arising from the Momenta buyout deal.
Mentions: JNJ
